Rocket Fuel
for Use
Important Safety
Prescribing Information Instructions for Use Important Safety Information Amgen MedInfo Live Assistance For Patients

Access for your patients

Neulasta® patients who need financial assistance for the Neulasta® Delivery Kit or prefilled syringe may be eligible for support from several sources. These include:

  • Independent co-pay foundations
  • The Safety Net Foundation, which provides Neulasta® at no cost for eligible patients
  • The Neulasta FIRST STEP® Co-Pay Coupon Program

Learn more about the Neulasta® Delivery Kit.

89% of Neulasta® patients had $0 out-of-pocket costs, based on a national claims database*1

*National claims database included 166,581 patients, across all insurance types, between January 2011 and August 2014.

Your patients may be eligible for the Neulasta® Co-Pay Coupon Program

The Neulasta FIRST STEP® Program is a co-pay coupon program to help commercially insured eligible patients with their deductible, co-insurance, and/or co-pay requirements for Neulasta® (pegfilgrastim).

Access coding and billing information for Neulasta.

Download the formulary fact sheet for Neulasta (includes On-body Injector and prefilled syringe).

Enrolling your practice

To enroll your practice in the Amgen FIRST STEP® Program, please call 1-888-65-STEP1 (1-888-657-8371). Offices must complete this process once prior to processing the Amgen FIRST STEP® Program Cards.


Learn about assistance for uninsured patients


  1. Data on file, Amgen.
Indication and Important Safety Information


Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.